In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity

Vaccine

Volumn 19, Issue 1, 2000, Pages 23-32

  Ludewig, Burkhard ^a   Barchiesi, Federica ^a   Pericin, Marcus ^a   Zinkernagel, Rolf M ^a   Hengartner, Hans ^a   Schwendener, Reto A ^b  

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antigenic peptides; Tumour immunity; Vaccination

Indexed keywords

LIPOSOME; VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; FEMALE; GLYCOPROTEINS; INJECTIONS, INTRADERMAL; INTERLEUKIN-1; LIPOSOMES; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 0034663576     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00163-8     Document Type: Article

References (38)

1. Kagi D., Ledermann B., Burki K., et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 369:1994;31-37.
2. van den Broek M.E., Kagi D., Ossendorp F., et al. Decreased tumour surveillance in perforin-deficient mice. J. Exp. Med. 184:1996;1781-1790.
3. Sahin U., Tureci O., Schmitt H., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA. 92:1995;11810-11813.
4. Van den Eynde B.J., van der Bruggen P. T cell defined tumour antigens. Curr. Opin. Immunol. 9:1997;684-693.
5. Berzofsky JA, Ahlers JD, Derby MA, et al., Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 1999; 170:151-72.
6. Pinto L.A., Berzofsky J.A., Fowke K.R., et al. HIV-specific immunity following immunisation with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. Aids. 13:1999;2003-2012.
7. van Driel W.J., Ressing M.E., Kenter G.G., et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer. 35:1999;946-952.
8. Aichele P., Brduscha-Riem K., Zinkernagel R.M., Hengartner H., Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182:1995;261-266.
9. Kast W.M., Roux L., Curren J., et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA. 88:1991;2283-2287.
10. Oxenius A., Martinic M.M., Hengartner H., Klenerman P. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J. Virol. 73:1999;4120-4126.
11. Kyburz D., Aichele P., Speiser D.E., et al. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23:1993;1956-1962.
12. Toes R.E., Blom R.J., Offringa R., Kast W.M., Melief C.J. Enhanced tumour outgrowth after peptide vaccination. Functional deletion of tumour-specific CTL induced by peptide vaccination can lead to the inability to reject tumours. J. Immunol. 156:1996;3911-3918.
13. Karrer U., Althage A., Odermatt B., et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-/-)) mutant mice. J. Exp. Med. 185:1997;2157-2170.
14. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
15. Flamand V., Sornasse T., Thielemans K., et al. Murine dendritic cells pulsed in vitro with tumour antigen induce tumour resistance in vivo. Eur. J. Immunol. 24:1994;605-610.
16. Mayordomo J.I., Zorina T., Storkus W.J., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nat. Med. 1:1995;1297-1302.
17. Ludewig B., Ehl S., Karrer U., et al. Dendritic cells efficiently induce protective antiviral immunity. J. Virol. 72:1998;3812-3818.
18. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
19. Thurner B., Haendle I., Roder C., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669-1678.
20. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today. 11:1990;89-97.
21. Oussoren C., Zuidema J., Crommelin D.J., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. Part II: Influence of liposomal size, lipid compostion and lipid dose. Biochim. Biophys. Acta. 1328:1997;261-272.
22. Nair S., Babu J.S., Dunham R.G., et al. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Virol. 67:1993;4062-4069.
23. Nair S., Zhou F., Reddy R., Huang L., Rouse B.T. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J. Exp. Med. 175:1992;609-612.
24. Fukasawa M., Shimizu Y., Shikata K., et al. Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett. 441:1998;353-356.
25. Serre K., Machy P., Grivel J.C., et al. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J. Immunol. 161:1998;6059-6067.
26. Ehl S., Hombach J., Aichele P., et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J. Exp. Med. 187:1998;763-774.
27. Oxenius A., Bachmann M.F., Zinkernagel R.M., Hengartner H. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 28:1998;390-400.
28. Battegay M., Cooper S., Althage A., et al. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods. 33:1991;191-198.
29. Carson D.A., Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. 186:1997;1621-1622.
30. Kalams S.A., Walker B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:1998;2199-2204.
31. Toes R.E., van der Voort E.I., Schoenberger S.P., et al. Enhancement of tumour outgrowth through CTL tolerisation after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160:1998;4449-4456.
32. Shirai M., Pendleton C.D., Ahlers J., et al. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 152:1994;549-556.
33. Ossendorp F., Mengede E., Camps M., Filius R., Melief C.J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumours. J. Exp. Med. 187:1998;693-702.
34. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 393:1998;474-478.
35. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:1998;480-483.
36. Cho B.K., Palliser D., Guillen E., et al. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity. 12:2000;263-272.
37. Sparwasser T., Koch E.S., Vabulas R.M., et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:1998;2045-2054.
38. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:1995;389-400.